Anthera Pharmaceuticals Inc news

   Watch this stock
Showing stories 1 - 10 of about 77   

Articles published

ANTH 10.71 +0.28 (2.68%)
price chart
Company Shares of Anthera Pharmaceuticals, Inc. Rally 0.93%
Shares of Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) rose by 0.93% in the past week and 32.08% for the last 4 weeks.
Short Interest in Anthera Pharmaceuticals Rises By 77.1% (ANTH)  Dakota Financial News
Zacks Rating on Anthera Pharmaceuticals, Inc.
Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) remains a strong buy in the latest set of rankings. The shares have received an average rating of 1 by 2 analysts.
Anthera Pharmaceuticals to Report 2015 Second Quarter and Operational Update ...  MarketWatch
Pre-Market News Buzz on: Anthera Pharmaceuticals (NASDAQ:ANTH), Marsh ...
Anthera Pharmaceuticals, Inc. (ANTH) declared that it plans to issue a press release reporting its 2015 second quarter and operational update after the close of the market on Monday, August 10, 2015.
Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) Analyst Rating Update
Anthera Pharmaceuticals (NASDAQ:ANTH) has received a short term rating of hold from research analysts at Zacks with a rank of 3. The company has been rated an average of 1 by 2 Wall Street Analysts. 2 analysts have added the shares in their list of ...
Anthera Pharmaceuticals Cut to "Hold" at Zacks (ANTH)  The Legacy
Current Trade Stocks Highlights: Sarepta Therapeutics (NASDAQ:SRPT), Anthera ...  wsnewspublishers
Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) Short Interest Update
Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) has seen a rise of 950,241 shares or 77.1% in the short interest. The remaining shorts are 7.6% of the total floated shares.
Company Shares of Anthera Pharmaceuticals, Inc. Rally 19.05%
Shares of Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) rose by 19.05% in the past week and 30.87% for the last 4 weeks.
Anthera Pharmaceuticals (ANTH) Set to Announce Quarterly Earnings on Monday  Dakota Financial News
Anthera Pharmaceuticals (ANTH) Scheduled to Post Earnings on Monday  The Legacy
Analyst Rating Update on Anthera Pharmaceuticals, Inc.
As many as 2 brokerage firms have rated Anthera Pharmaceuticals (NASDAQ:ANTH) at 1. Research Analysts at Zacks have ranked the company at 3, suggesting the traders with a rating of hold for the short term. 2 analysts rated the company as a strong buy.
Anthera Pharmaceuticals Inc (NASDAQ:ANTH) on Watch
[Benzinga] Anthera Pharmaceuticals Inc (NASDAQ:ANTH)(TREND ANALYSIS) announced that it has completed the previously announced underwritten public offering of 3,833,334 shares of its common stock, offered at a price of $7.50 per share, which ...
Anthera Pharmaceuticals (ANTH) Looks Good: Stock Up 13%  Zacks.com
Anthera Pharmaceuticals Short Interest Up 46.8% in June (ANTH)  Dakota Financial News
Analyst Price Target Update on Anthera Pharmaceuticals, Inc.
Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) should head towards $9.75 per share according to 2 Analysts in consensus.
Company Shares of Anthera Pharmaceuticals, Inc. Rally 9.07%
Shares of Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) appreciated by 9.07% during the past week but lost 1.41% on a 4-week basis.